Yanbing Zhou, PhD

Merck

Disclosure(s): Merck: I am a full time Merck Employee and own stocks in the retirement plan provided by Merck., Stocks/Bonds (Public Company)

Poster(s):

• (P-1074) Clinical Outcomes in Patients Hospitalized with Exacerbation of Chronic Respiratory Infections treated with Ceftolozane/Tazobactam: Results from SPECTRA
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1075) Treatment Patterns among Hospitalized Patients with Gram-Negative Infection Treated with Imipenem/Cilastatin/Relebactam (I/R): Retrospective US-based EHR Medical Chart Review
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1076) Describing the clinical characteristics, treatment patterns, and outcomes in hospitalized pneumonia patients treated with Ceftolozane/Tazobactam (C/T): Insights from the SPECTRA Study
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1077) Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam (C/T) Real-world Analysis (SPECTRA): Clinical Outcomes and Treatment Patterns from Mexico
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1105) Effectiveness of Imipenem-Relebactam for Multidrug-resistant Pseudomonas aeruginosa in Pneumonia and Bloodstream Infections in the United States (MIRAGE)
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1113) Treatment Patterns and Clinical Outcomes in Hospitalized Patients with Febrile Neutropenia treated with Ceftolozane/Tazobactam: A Subgroup Analysis of the SPECTRA study
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1537) Comparative effectiveness of early treatment with ceftolozane/tazobactam (C/T) relative to polymyxin (PB)-based therapy for non-COVID-19 patients (pts) with pneumonia (PNA) due to multi-drug resistant Pseudomonas aeruginosa (MDR-PSA) across US Hospitals
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-2305) Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam [C/T] Real-world Analysis Results (SPECTRA): Results of the Immunocompromised Patients
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT